New Indications for Pembrolizumab Top SPT Week in Review

5. FDA Grants Priority Review to Rituximab for Children with 2 Rare Forms of Vasculitis

Genentech is seeking approval for rituximab (Rituxan) with glucocorticoids for pediatric patients with granulomatosis with polyangiitis and microscopic polyangiitis. Read more.

4. Mental Health Care in HIV Clinics Proves Beneficial

Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population. Read more.

3. FDA Approves Fifth Trastuzumab Biosimilar

The approval of Amgen’s trastuzumab-anns, the fifth biosimilar to Herceptin, marks the twentieth biosimilar approved by the FDA. Read more.

2. FDA Approves Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab vedotin-piiq (Polivy) is a first-of-its-kind anti-CD76b antibody-drug conjugate used in combination with bendamustine plus rituximab (Rituxan) for previously-treated diffuse large B-cell lymphoma. Read more.

1.FDA OKs Pembrolizumab for New Indications in Head and Neck Squamous Cell Carcinoma

Pembrolizumab is now indicated for use as a first-line monotherapy treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma. Read more.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$